Evidence map›Paper›PMID 24835176›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2014

Synthetic di-sulfated iduronic acid attenuates asthmatic response by blocking T-cell recruitment to inflammatory sites.

Motohiro Nonaka, Xingfeng Bao, Fumiko Matsumura, Sebastian Götze, Jeyakumar Kandasamy, Andrew Kononov, David H Broide, Jun Nakayama, Peter H Seeberger, Minoru Fukuda

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Synthesis of Sulfated Carbohydrates - Glycosaminoglycans.Handbook of experimental pharmacology · 2025
    Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Heparin Mimetics: Their Therapeutic Potential.Pharmaceuticals (Basel, Switzerland) · 2017
    Review
  11. Review
  12. Article
  13. Chemokines and Glycosaminoglycans.Frontiers in immunology · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

Motohiro NonakaGlycobiology Unit, Sanford-Burnham Medical Research Institute, La Jolla, CA 92037;
Xingfeng BaoGlycobiology Unit, Sanford-Burnham Medical Research Institute, La Jolla, CA 92037;
Fumiko MatsumuraGlycobiology Unit, Sanford-Burnham Medical Research Institute, La Jolla, CA 92037;Department of Biomolecular Systems, Max Planck Institute for Colloids and Interfaces, 14476 Potsdam, Germany;
Sebastian GötzeDepartment of Biomolecular Systems, Max Planck Institute for Colloids and Interfaces, 14476 Potsdam, Germany;Institute of Chemistry and Biochemistry, Freie Universität Berlin, 14195 Berlin, Germany;
Jeyakumar KandasamyDepartment of Biomolecular Systems, Max Planck Institute for Colloids and Interfaces, 14476 Potsdam, Germany;Institute of Chemistry and Biochemistry, Freie Universität Berlin, 14195 Berlin, Germany;
Andrew KononovDepartment of Biomolecular Systems, Max Planck Institute for Colloids and Interfaces, 14476 Potsdam, Germany;
David H BroideDepartment of Medicine, University of California, San Diego, La Jolla, CA 92093; and.
Jun NakayamaDepartment of Molecular Pathology, Shinshu University Graduate School of Medicine, Matsumoto 390-8621, Japan.
Peter H SeebergerDepartment of Biomolecular Systems, Max Planck Institute for Colloids and Interfaces, 14476 Potsdam, Germany;Institute of Chemistry and Biochemistry, Freie Universität Berlin, 14195 Berlin, Germany;
Minoru FukudaGlycobiology Unit, Sanford-Burnham Medical Research Institute, La Jolla, CA 92037; minoru@sanfordburnham.org.
Max Planck Institute of Colloids and Interfaces · DESanford Burnham Prebys Medical Discovery Institute · USFreie Universität Berlin · DEMax Planck Society · DEShinshu University · JPUniversity of California, San Diego · US

Funding

TRM and airway inflammation and remodelingU19AI070535 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROIDE, DAVID H · 2006 to 2025
$34.2M
THE A(1,3)FUCOSYLTRANSFERASE GENES AND SELECTIN LIGAND EXPRESSIONP01CA071932 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI FUKUDA, MINORU · 1996 to 2012
$15.5M
Chromosome 17q, allergic inflammation, and remodelingR01AI107779 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROIDE, DAVID H · 2013 to 2024
$4.7M
Eosinophil trafficking and chronic tissue damage induced by allergic inflammationR37AI038425 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROIDE, DAVID H · 2007 to 2016
$3.7M
Eosinophil TraffickingR01AI038425 · NIAID · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI BROIDE, DAVID H · 1996 to 2005
$1.8M
Siglec-F and Resolution of Allergic InflammationR01AI072115 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROIDE, DAVID H · 2008 to 2012
$1.7M
NCI NIH HHS P01 CA071932NCI NIH HHS P01 CA71932NIAID NIH HHS AI 107779NIAID NIH HHS AI 38425NIAID NIH HHS AI 70535NIAID NIH HHS AI 72115NIAID NIH HHS R01 AI038425NIAID NIH HHS R01 AI072115NIAID NIH HHS R01 AI107779NIAID NIH HHS R37 AI038425NIAID NIH HHS U19 AI070535
6 · The paper itself

Abstract

Identification of carbohydrate sequences that determine affinity to specific chemokines is a critical step for strategies to interfere with chemokine-mediated leukocyte trafficking. Here, we first characterized the development of allergic asthma in Tie2-dependent and inducible Ext1-knockout (Tie2-Ext1(iKO)) mice. We showed that heparan sulfate is essential for leukocyte recruitment in the peribronchial region and bronchoalveolar lavage fluid (BALF), and is crucial for induction of airway hyperresponsiveness. Our glycan microarray showed a unique affinity profile of chemokine CCL20 to substructures of heparin and heparin-like oligo/di/monosaccharides. Among them, we identified a synthetic and not naturally occurring monosaccharide, 2,4-O-di-sulfated iduronic acid (Di-S-IdoA), as a potential inhibitor for CCL20-heparan sulfate interaction. Mice injected with Di-S-IdoA via tail vain or nasal inhalation showed attenuated leukocyte recruitment into inflammatory sites and BALF. These results demonstrate a critical role of chemokine-heparan sulfate interaction in the asthma development and Di-S-IdoA as a potential drug for asthma treatment.

Indexed as

AnimalsAsthmaBronchoalveolar Lavage FluidCarbohydrate SequenceChemokine CCL20ChemotaxisDisease Models, AnimalEosinophilsExostosin 1Heparan SulfateIduronic AcidLungMiceMice, KnockoutN-AcetylglucosaminyltransferasesOvalbuminCCL20 protein, mouseChemokine CCL20Exostosin 1Heparan SulfateIduronic AcidN-AcetylglucosaminyltransferasesOvalbuminPolysaccharidesReceptor, TIE-2SulfatesTek protein, mouselymphocyte recruitmentsulfated monosaccharide

Identifiers

PMID24835176
PMCPMC4050563
OpenAlexW2082446710

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.